EstoniaTuberculosis profile
Population  2016 1.3 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.016 (0.016–0.016) 1.2 (1.2–1.2)
Mortality (HIV+TB only) <0.01 (<0.01–<0.01) 0.27 (0.18–0.38)
Incidence  (includes HIV+TB) 0.22 (0.18–0.25) 16 (14–19)
Incidence (HIV+TB only) 0.023 (0.015–0.033) 1.8 (1.1–2.5)
Incidence (MDR/RR-TB)** 0.046 (0.031–0.06) 3.5 (2.3–4.6)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 0.01 (<0.01–0.012) 0.068 (0.058–0.078) 0.078 (0.066–0.09)
Males 0.011 (<0.01–0.012) 0.13 (0.11–0.15) 0.14 (0.12–0.16)
Total 0.021 (0.018–0.024) 0.2 (0.17–0.22) 0.22 (0.18–0.25)
TB case notifications, 2016  
Total cases notified 192
Total new and relapse 188
          - % tested with rapid diagnostics at time of diagnosis 76%
          - % with known HIV status 95%
          - % pulmonary 93%
          - % bacteriologically confirmed among pulmonary 86%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 87% (75–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.09 (0.08–0.11)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 21 12%
          - on antiretroviral therapy 20 95%
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  34
(23–45)
Estimated % of TB cases with MDR/RR-TB 14% (8.3–21) 54% (25–81)  
% notified tested for rifampicin resistance 83% 84% 160
MDR/RR-TB cases tested for resistance to second-line drugs   26
Laboratory-confirmed cases MDR/RR-TB: 26, XDR-TB: 7
Patients started on treatment **** MDR/RR-TB: 25, XDR-TB: 6
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 83% 172
Previously treated cases, excluding relapse, registered in 2015 100% 2
HIV-positive TB cases registered in 2015 81% 16
MDR/RR-TB cases started on second-line treatment in 2014 74% 42
XDR-TB cases started on second-line treatment in 2014 13% 8
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2017  
National TB budget (US$ millions) 1.2
Funding source: 100% domestic, 0% international, 0% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-11-17 Data: www.who.int/tb/data